Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Prothena Corp (PRTA)
Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,581,943
  • Shares Outstanding, K 52,564
  • Annual Sales, $ 53,910 K
  • Annual Income, $ -116,950 K
  • 60-Month Beta 0.41
  • Price/Sales 46.94
  • Price/Cash Flow N/A
  • Price/Book 3.74
Trade PRTA with:

Options Overview Details

View History
  • Implied Volatility 61.91% ( +0.38%)
  • Historical Volatility 40.93%
  • IV Percentile 6%
  • IV Rank 6.36%
  • IV High 134.30% on 11/14/22
  • IV Low 56.99% on 03/03/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 155
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 2,284
  • Open Int (30-Day) 3,862

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.82
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -1.19
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -5.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.44 +2.78%
on 03/13/23
57.59 -17.12%
on 02/27/23
-4.37 (-8.39%)
since 02/22/23
3-Month
46.44 +2.78%
on 03/13/23
61.43 -22.30%
on 12/29/22
-11.03 (-18.77%)
since 12/22/22
52-Week
21.06 +126.64%
on 06/16/22
66.47 -28.19%
on 11/30/22
+9.98 (+26.44%)
since 03/22/22

Most Recent Stories

More News
Prothena to Participate in Stifel 2023 Virtual CNS Days

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 47.50 (-3.30%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.095 (+11.76%)
BIIB : 263.40 (-1.03%)
PRTA : 47.50 (-3.30%)
ITCI : 45.90 (-0.61%)
RHHBY : 35.4500 (-0.48%)
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced broad...

PRTA : 47.50 (-3.30%)
With Alzheimer’s Cases Set to Explode in the Near-Term, New Treatments and Diagnostics are Needed

USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for developing Alzheimer’s disease increases by 50-80% in older adults who caught COVID-19....

MRVL.VN : 0.095 (+11.76%)
BIIB : 263.40 (-1.03%)
PRTA : 47.50 (-3.30%)
ITCI : 45.90 (-0.61%)
RHHBY : 35.4500 (-0.48%)
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

RHHBY : 35.4500 (-0.48%)
BMY : 67.51 (+0.63%)
NVO : 147.18 (-0.07%)
PRTA : 47.50 (-3.30%)
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 47.50 (-3.30%)
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 47.50 (-3.30%)
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced...

PRTA : 47.50 (-3.30%)
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced positive...

PRTA : 47.50 (-3.30%)
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

BIIB : 263.40 (-1.03%)
RHHBY : 35.4500 (-0.48%)
PRTA : 47.50 (-3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 51.28
2nd Resistance Point 50.56
1st Resistance Point 49.84
Last Price 47.50
1st Support Level 48.40
2nd Support Level 47.68
3rd Support Level 46.96

See More

52-Week High 66.47
Fibonacci 61.8% 49.12
Last Price 47.50
Fibonacci 50% 43.76
Fibonacci 38.2% 38.41
52-Week Low 21.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar